Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib

被引：62

作者：

Jones, Jeffrey A. ^{[1
]}

Hillmen, Peter ^{[2
]}

Coutre, Steven ^{[3
]}

Tam, Constantine ^{[4
,5
]}

Furman, Richard R. ^{[6
]}

Barr, Paul M. ^{[7
]}

Schuster, Stephen J. ^{[8
]}

Kipps, Thomas J. ^{[9
]}

Flinn, Ian W. ^{[10
]}

Jaeger, Ulrich ^{[11
]}

Burger, Jan A. ^{[12
]}

Cheng, Mei ^{[13
]}

Ninomoto, Joi ^{[13
]}

James, Danelle F. ^{[13
]}

Byrd, John C. ^{[1
]}

O'Brien, Susan M. ^{[12
,14
]}

机构：

[1] Ohio State Univ, Div Hematol, A350B Starling Loving Hall,320 West 10th Ave, Columbus, OH 43210 USA

[2] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] St Vincents Hosp, Melbourne, Vic, Australia

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA

[8] Univ Penn, Div Hematol Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[10] Sarah Cannon Res Inst, Nashville, TN USA

[11] Med Univ Vienna, Vienna, Austria

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[13] Pharmacyclics LLC, Sunnyvale, CA USA

[14] Univ Calif Irvine, Irvine, CA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2017年 / 178卷 / 02期

关键词：

anticoagulation; bleeding; chronic lymphocytic leukaemia; haemorrhage; ibrutinib; X-LINKED AGAMMAGLOBULINEMIA; BRUTONS TYROSINE KINASE; PLATELET ACTIVATION; FOLLOW-UP; COLLAGEN; ABSENCE;

D O I：

10.1111/bjh.14660

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single-agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib-treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.

引用

页码：286 / 291

页数：6

共 15 条

[1] [Anonymous], BLOOD
[2] Tec regulates platelet activation by GPVI in the absence of Btk
Atkinson, BT
Ellmeier, W
Watson, SP
[J]. BLOOD, 2003, 102 (10) : 3592 - 3599
[3] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C.
Brown, J. R.
O'Brien, S.
Barrientos, J. C.
Kay, N. E.
Reddy, N. M.
Coutre, S.
Tam, C. S.
Mulligan, S. P.
Jaeger, U.
Devereux, S.
Barr, P. M.
Furman, R. R.
Kipps, T. J.
Cymbalista, F.
Pocock, C.
Thornton, P.
Caligaris-Cappio, F.
Robak, T.
Delgado, J.
Schuster, S. J.
Montillo, M.
Schuh, A.
de Vos, S.
Gill, D.
Bloor, A.
Dearden, C.
Moreno, C.
Jones, J. J.
Chu, A. D.
Fardis, M.
McGreivy, J.
Clow, F.
James, D. F.
Hillmen, P.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 213 - 223
[4] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Byrd, John C.
Furman, Richard R.
Coutre, Steven E.
Burger, Jan A.
Blum, Kristie A.
Coleman, Morton
Wierda, William G.
Jones, Jeffrey A.
Zhao, Weiqiang
Heerema, Nyla A.
Johnson, Amy J.
Shaw, Yun
Bilotti, Elizabeth
Zhou, Cathy
James, Danelle F.
O'Brien, Susan
[J]. BLOOD, 2015, 125 (16) : 2497 - 2506
[5] Farooqui M., 2015, Blood, V126, P2933, DOI [10.1182/blood.V126.23.2933.2933, DOI 10.1182/BLOOD.V126.23.2933.2933]
[6] Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females
Futatani, T
Watanabe, C
Baba, Y
Tsukada, S
Ochs, HD
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (01) : 141 - 149
[7] Incidence of Major Hemorrhage Among CLL and MCL Patients Compared to the General Elderly Population: An Analysis of the US SEER-Medicare Linked Database
Gifkins, Dina M.
Matrho, Amy
Yang, Huiying
Xu, Yimei
Gooden, Mary Ann
Wildgust, Mark
[J]. BLOOD, 2015, 126 (23)
[8] Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
Kamel, S.
Horton, L.
Ysebaert, L.
Levade, M.
Burbury, K.
Tan, S.
Cole-Sinclair, M.
Reynolds, J.
Filshie, R.
Schischka, S.
Khot, A.
Sandhu, S.
Keating, M. J.
Nandurkar, H.
Tam, C. S.
[J]. LEUKEMIA, 2015, 29 (04) : 783 - 787
[9] Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Levade, Marie
David, Elodie
Garcia, Cedric
Laurent, Pierre-Alexandre
Cadot, Sarah
Michallet, Anne-Sophie
Bordet, Jean-Claude
Tam, Constantine
Sie, Pierre
Ysebaert, Loic
Payrastre, Bernard
[J]. BLOOD, 2014, 124 (26) : 3991 - 3995
[10] Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib
Lipsky, Andrew H.
Farooqui, Mohammed Z. H.
Tian, Xin
Martyr, Sabrina
Cullinane, Ann M.
Nghiem, Khanh
Sun, Clare
Valdez, Janet
Niemann, Carsten U.
Herman, Sarah E. M.
Saba, Nakhle
Soto, Susan
Marti, Gerald
Uzel, Gulbu
Holland, Steve M.
Lozier, Jay N.
Wiestner, Adrian
[J]. HAEMATOLOGICA, 2015, 100 (12) : 1571 - 1578

← 1 2 →